Sector ratings MannKind Corporation

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 12/02/2026 GMT			5-day change	1st Jan Change
5.630 ^USD	-1.92%		+2.18%	-0.71%

02-09	MannKind Enrolls First Patient in Study Evaluating Afrezza Inhaled Insulin in Youth	MT
02-09	MannKind announces first patient enrolled in Inhale-1st pediatric study evaluating Afrezza® for youth with newly-diagnosed type 1 diabetes (T1d)	RE

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
MANNKIND CORPORATION	1.73B	-	BBB	-		-
ARGENX SE	51.05B		AA
WUXI APPTEC CO., LTD.	45.62B		AAA
INSMED INCORPORATED	31.17B	-	BBB	-		-
BIONTECH SE	26.54B	-	-	-		-
WUXI BIOLOGICS (CAYMAN) INC.	21.88B		AAA
GENMAB A/S	18.4B		AA
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	12.63B	-	A	-		-
AKESO, INC.	12.22B		B			-
SUMMIT THERAPEUTICS INC.	11.28B	-	-	-		-
EXELIXIS, INC.	11.09B		BB
MADRIGAL PHARMACEUTICALS, INC.	10.76B	-	B	-		-
SAMSUNG EPIS HOLDINGS CO., LTD.	10.55B	-	-	-		-	-
ARROWHEAD PHARMACEUTICALS, INC.	8.74B	-	BBB	-		-
PHARMAESSENTIA CORPORATION	8.53B		AA
CEREVEL THERAPEUTICS HOLDINGS, INC.	8.19B	-	-	-	-	-	-	-
CYTOKINETICS, INCORPORATED	7.95B	-	AA	-		-
NUVALENT, INC.	7.87B	-	CCC	-		-
VAXCYTE, INC.	7.89B	-	BBB	-		-
REMEGEN CO., LTD.	7.42B		-			-
Average	16.08B		A
Weighted average by Cap.			A